{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:56:33Z","timestamp":1764194193342},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1097\/rlu.0000000000001448","type":"journal-article","created":{"date-parts":[[2016,10,22]],"date-time":"2016-10-22T11:27:17Z","timestamp":1477135637000},"page":"44-46","source":"Crossref","is-referenced-by-count":14,"title":["Erythema Nodosum\u2013Like Panniculitis as a False-Positive 18F-FDG PET\/CT in Advanced Melanoma Treated With Dabrafenib and Trametinib"],"prefix":"10.1097","volume":"42","author":[{"given":"Isabel","family":"Mart\u00ednez-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Garc\u00eda-Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remedios","family":"Quirce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Jim\u00e9nez-Bonilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Banzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210204","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.pathol.3.121806.151541","article-title":"Molecular pathogenesis of cutaneous melanocytic neoplasms","volume":"4","author":"Ibrahim","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"R2-9-20210204","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAFV600E: implications for carcinogenesis and molecular therapy","volume":"10","author":"Cantwell-Dorris","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"R3-9-20210204","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"R4-9-20210204","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/2191-219X-2-22","article-title":"FDG-PET is a good biomarker of both early response and acquired resistance in BRAFV600 mutant melanomas treated with vemurafenib and the MEK inhibitor GDC-0973","volume":"2","author":"Baudy","year":"2012","journal-title":"EJNMMI Res"},{"key":"R5-9-20210204","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"R6-9-20210204","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"R7-9-20210204","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R8-9-20210204","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"R9-9-20210204","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R10-9-20210204","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MNM.0000000000000406","article-title":"Correlation between early 18F-FDG PET\/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma","volume":"37","author":"Schmitt","year":"2016","journal-title":"Nucl Med Commun"},{"key":"R11-9-20210204","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1684\/ejd.2014.2512","article-title":"Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor","volume":"25","author":"Galliker","year":"2015","journal-title":"Eur J Dermatol"},{"key":"R12-9-20210204","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.13039","article-title":"Erythema nodosum-like lesions during BRAF inhibitor therapy: report on 16 new cases and review of the literature","volume":"29","author":"Mossner","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R13-9-20210204","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1097\/RLU.0000000000001027","article-title":"BRAF inhibitor-induced panniculitis: appearance on 18F-FDG PET\/CT","volume":"41","author":"Broski","year":"2016","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000001448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:17:07Z","timestamp":1620973027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201701000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000001448","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}